GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » PE Ratio (TTM)

T2 Biosystems (T2 Biosystems) PE Ratio (TTM) : At Loss (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-25), T2 Biosystems's share price is $2.74. T2 Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.00. Therefore, T2 Biosystems's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for T2 Biosystems's PE Ratio (TTM) or its related term are showing as below:

TTOO' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



TTOO's PE Ratio (TTM) is ranked worse than
100% of 97 companies
in the Medical Diagnostics & Research industry
Industry Median: 31.24 vs TTOO: At Loss

T2 Biosystems's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-2.55. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.00.

As of today (2024-04-25), T2 Biosystems's share price is $2.74. T2 Biosystems's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-140.22. Therefore, T2 Biosystems's PE Ratio without NRI for today is At Loss.

During the past 12 years, T2 Biosystems's highest PE Ratio without NRI was 94.18. The lowest was 0.00. And the median was 77.46.

T2 Biosystems's EPS without NRI for the three months ended in Dec. 2023 was $-2.56. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-140.22.

During the past 3 years, the average EPS without NRI Growth Rate was 78.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.60% per year.

During the past 12 years, T2 Biosystems's highest 3-Year average EPS without NRI Growth Rate was 78.20% per year. The lowest was -132.40% per year. And the median was 14.70% per year.

T2 Biosystems's EPS (Basic) for the three months ended in Dec. 2023 was $-2.55. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-146.00.


T2 Biosystems PE Ratio (TTM) Historical Data

The historical data trend for T2 Biosystems's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems PE Ratio (TTM) Chart

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

T2 Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of T2 Biosystems's PE Ratio (TTM)

For the Diagnostics & Research subindustry, T2 Biosystems's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems's PE Ratio (TTM) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's PE Ratio (TTM) falls into.



T2 Biosystems PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

T2 Biosystems's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=2.74/-145.998
=At Loss

T2 Biosystems's Share Price of today is $2.74.
T2 Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-146.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


T2 Biosystems  (NAS:TTOO) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


T2 Biosystems PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421